PDCD1 and neoplasm: Ipilimumab and Nivolumab promote anti-tumor immunity by targeting, respectively, the cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor and the programmed cell death protein-1 (PD-1) receptor, which transmit inhibitory signals to T cells.